Publisher of Iranian Journals and Conference Proceedings

Please waite ..
CIVILICAWe Respect the Science
Publisher of Iranian Journals and Conference Proceedings
عنوان
Paper

Safety and Quality of Life in the Treatment of Non-Metastasic Colorectal Cancer patients: 5-Fluorouracil versus Capecitabine

تعداد صفحات: 12 | تعداد نمایش خلاصه: 102 | نظرات: 0
سال انتشار: 1398
کد COI Paper: CANCER01_006
زبان Paper: Englishglish
(فایل این Paper در 12 صفحه با فرمت PDF قابل دریافت می باشد)

راهنمای دانلود فایل کامل این Paper

اگر در مجموعه سیویلیکا عضو نیستید، به راحتی می توانید از طریق فرم روبرو اصل این Paper را خریداری نمایید.

با عضویت در سیویلیکا می توانید اصل مقالات را با حداقل ۳۳ درصد تخفیف (دو سوم قیمت خرید تک Paper) دریافت نمایید. برای عضویت در سیویلیکا به صفحه ثبت نام مراجعه نمایید.در صورتی که دارای نام کاربری در مجموعه سیویلیکا هستید، ابتدا از قسمت بالای صفحه با نام کاربری خود وارد شده و سپس به این صفحه مراجعه نمایید.

لطفا قبل از اقدام به خرید اینترنتی این Paper، ابتدا تعداد صفحات Paper را در بالای این صفحه کنترل نمایید.

برای راهنمایی کاملتر راهنمای سایت را مطالعه کنید.

خرید و دانلود فایل Paper

با استفاده از پرداخت اینترنتی بسیار سریع و ساده می توانید اصل این مقاله را که دارای 12 صفحه است در اختیار داشته باشید.

قیمت این مقاله : 3,000 تومان

آدرس ایمیل خود را در کادر زیر وارد نمایید:

مشخصات نویسندگان Paper Safety and Quality of Life in the Treatment of Non-Metastasic Colorectal Cancer patients: 5-Fluorouracil versus Capecitabine

J Sánchez-Gudín - Hospital Pharmacy Department. Virgen de la Luz Hospital, Hermandad de Donantes de Sangre, 16002, Cuenca (Spain)
C Martín-Sabroso - Department of Pharmaceutics and Food Technology, Complutense University, 28040 Madrid (Spain)
A.M Fernández-Carballido - Department of Pharmaceutics and Food Technology, Complutense University, 28040 Madrid (Spain)
D Barreda-Hernández - Hospital Pharmacy Department. Virgen de la Luz Hospital, Hermandad de Donantes de Sangre, 16002, Cuenca (Spain)
A.I Torres-Suárez - Department of Pharmaceutics and Food Technology, Complutense University, 28040 Madrid (Spain)

چکیده Paper:

Colorectal cancer (CRC) is the most frequent neoplasm of the digestive system and the third most frequent tumour worldwide. In stages I and II the treatment is only surgical and, in high-risk stages II and stages III surgery is complemented with adjuvant chemotherapy. Traditional adjuvant therapy consists of 5-fluorouracil, in combination with leucovorin, and oxaliplatin (FOLFOX regimen, all for iv administration). Alternatively 5-fluorouracil can be substituted by capecitabine, precursor of 5-fluorouracil, which has the advantage that it is administered orally (XELOX regimen). Both regimes are considered interchangeable. The aim of this study is to compare these regimens (FOLFOX and XELOX) in terms of safety and quality of life (QoL) in patients diagnosed with stage II and III non-metastatic CRC. For this purpose, a descriptive prospective study with patients diagnosed with stage II and III non-metastatic CRC in adjuvant treatment with FOLFOX and XELOX schemes was carried out. The appearance of symptomatic, haematological and hepatic adverse events (AE) during the treatment was established by evaluating their clinical and pharmacotherapeutic history. The severity of the AE was established following the Common Terminology Criteria for Adverse Events (CTCAE v.4.03). To evaluate the QoL, the QoL EORTC QLQ-C30 version 3.0 questionnaire was given to patients at the beginning and the middle of the adjuvant treatment. The statistical analysis of the data was carried out with the SPSS®15.0 program. 33 patients were finally included in the study. All the patients treated with FOLFOX and with XELOX presented some of the AE studied. The most frequent AE for both groups were neurotoxicity, diarrhoea, constipation and thrombocytopenia, but only statistically significant difference was found in case of palmar-plantar erythrodysesthesia síndrome (PPE), and more frequent in patients treated with XELOX. According to QoL, patients with FOLFOX presented a worsening in terms of daily activities, constipation and insomnia while in those treated with XELOX a worsening in daily activities, constipation, fatigue, nausea, vomiting, anorexia and diarrhoea was observed. Only statistically significant difference was found in the emotional role item at the middle of the treatment, at which point, patients treated with FOLFOX were better emotionally than those treated with XELOX. As conclusion, both schemes seem to be safe, although differences in PPE (more frequent with XELOX) and emotional role (better with FOLFOX) were found. However, it should be taken into account that patients treated with FOLFOX presented higher frequency of haematological AE, which are difficult to perceive. In contrast, patients treated with XELOX had higher frequency of symptomatic AE, which probably leads to this slightly worse QoL.

کلیدواژه ها:

Colorectal Cancer,Safety,Quality Of Life,5-Fluorouracil,Capecitabine

کد Paper/لینک ثابت به این Paper

برای لینک دهی به این Paper می توانید از لینک زیر استفاده نمایید. این لینک همیشه ثابت است و به عنوان سند ثبت Paper در مرجع سیویلیکا مورد استفاده قرار میگیرد:

https://civilica.com/doc/963390/

کد COI Paper: CANCER01_006

نحوه استناد به Paper:

در صورتی که می خواهید در اثر پژوهشی خود به این Paper ارجاع دهید، به سادگی می توانید از عبارت زیر در بخش منابع و مراجع استفاده نمایید:
undefined, undefined و undefined, undefined و undefined, undefined و undefined, undefined و undefined, undefined,1398,Safety and Quality of Life in the Treatment of Non-Metastasic Colorectal Cancer patients: 5-Fluorouracil versus Capecitabine,همایش بین المللی تحقیقات سرطان 2019,,,https://civilica.com/doc/963390

در داخل متن نیز هر جا که به عبارت و یا دستاوردی از این Paper اشاره شود پس از ذکر مطلب، در داخل پارانتز، مشخصات زیر نوشته می شود.
برای بار اول: (1398, Sánchez-Gudín, J؛ C Martín-Sabroso و A.M Fernández-Carballido و D Barreda-Hernández و A.I Torres-Suárez)
برای بار دوم به بعد: (1398, Sánchez-Gudín؛ Martín-Sabroso و Fernández-Carballido و Barreda-Hernández و Torres-Suárez)
برای آشنایی کامل با نحوه مرجع نویسی لطفا بخش راهنمای سیویلیکا (مرجع دهی) را ملاحظه نمایید.

Research Info Management

Certificate | Report Paper
این Paper در بخشهای موضوعی زیر دسته بندی شده است:
  • علوم پزشکی > سرطان
  • Export Citation info of this Paper to research management softwares

    New RelatedPapers

    Share this paper

    WHAT IS COI?

    COI is a national code dedicated to all Iranian Conference and Journal Papers. the COI of each paper can be verified online.

    Support